Association of HLA class i antigen abnormalities with disease progression and early recurrence in prostate cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 529-540

  Seliger, Barbara ^a   Stoehr, Robert ^b   Handke, Diana ^a   Mueller, Anja ^a   Ferrone, Soldano ^c   Wullich, Bernd ^b   Tannapfel, Andrea ^d   Hofstaedter, Ferdinand ^e   Hartmann, Arndt ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antigen processing machinery; Hla class i antigens; Immune escape; Prostate cancer

Indexed keywords

BETA 2 MICROGLOBULIN; CALNEXIN; CALRETICULIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1 HEAVY CHAIN; LOW MOLECULAR WEIGHT PROTEIN 2; LOW MOLECULAR WEIGHT PROTEIN 7; MEMBRANE PROTEIN; PROTEIN P57; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR IMMUNITY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR RECURRENCE;

AGED; ANTIGEN PRESENTATION; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77449133036     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0769-5     Document Type: Article

References (55)

1. Epstein JI, Algabe F, Allsbrook WC, Bastacky S (2004) Tumours of the prostate. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA et al (eds) World Health Organization, classification of tumours. Pathology and genetic. Tumours of the urinary system and male genital organs. IARC, Lyon, pp 159-216
2. Thompson TC (1990) Growth factors and oncogenes in prostate cancer. Cancer cells 2: 345-354 (Pubitemid 20384141)
3. Risk M, Corman JM (2009) The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol 11: 16-27
4. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC (2003) Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52: 497-505 (Pubitemid 36963211)
5. Wang YS, Tsang YW, Chi CH, Cahng CC, Chu RM, Chi KH (2008) Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett 266: 275-285
6. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694-708
7. Olson WC, Heston WD, Rajasekaran AK (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2: 182-190 (Pubitemid 47554839)
8. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815 (Pubitemid 46952950)
9. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69: 609-615
10. Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL (2007) Phase I trail of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5: 347-350 (Pubitemid 47265557)
11. Slovin SF (2008) Pitfalls or promise in prostate cancer immunotherapy which is winning? Cancer J 14: 26-34
12. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6: 2175-2182
13. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW (2000) A phase I trial of a recombinant vaccina virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6: 1632-1638 (Pubitemid 30305054)
14. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG (2001) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cell engineered to secrete granulocyte-macrophage colonystimulating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168
15. Hammer GE, Kanaseki T, Shastri N (2007) The final touches make perfect the peptide-MHC class I repertoire. Immunity 26: 397-406 (Pubitemid 46603005)
16. Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8: 1041-1048 (Pubitemid 47423752)
17. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601: 123-131
18. Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 1: 264-268 (Pubitemid 46625898)
19. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumor from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273
20. Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118: 129-138 (Pubitemid 41681589)
21. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87: 280-285
22. Lee HM, Timme TL, Thompson TC (2000) Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60: 1927-1933
23. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS (1994) Modulated expression of human leukocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 74: 609-616 (Pubitemid 24348629)
24. Setiadi AF, David MD, Chen SS, Hiscott J, Jefferies WA (2005) Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res 65: 7485-7492 (Pubitemid 41161284)
25. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 178: 692-696 (Pubitemid 47030489)
26. Stolzenburg JU, Rabenalt R, Do M, Kallidonis P, Liatsikos EN (2008) Endoscopic extraperitoneal radical prostatectomy: the University of Leipzig experience of 2000 cases. J Endourol 22: 2319-2325
27. Sobin LH, Wittekind C (1997) TNM classification of malignant tumours. Wiley-Liss, New York, pp 172-175
28. Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Castaños-Vélez E, Lehmann K (2005) Expression levels of putative zinc transporter LIV-I are associated with a better outcome of breast cancer patients. Int J Cancer 117: 961-973 (Pubitemid 41688571)
29. van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A (2007) FGFR3 mutations and normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumors. Eur Urol 52: 760-768 (Pubitemid 47126132)
30. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137: 2299-2306 (Pubitemid 16020728)
31. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171: 1918-1926 (Pubitemid 36966475)
32. Lampson LA, Fisher CA, Whelan JP ( 1983) Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 30: 2471-2478
33. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66: 185-194 (Pubitemid 41243306)
34. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigenspecific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J. Immunol. Methods 299: 139-151 (Pubitemid 40725931)
35. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62: 382-393 (Pubitemid 37338878)
36. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8: 85-95 (Pubitemid 19082761)
37. Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 66: 6387-6394
38. Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171: 885-889
39. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesonero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based-study. Cancer Res 59: 2011-2017 (Pubitemid 29186179)
40. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S (2003) Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 95: 1721-1727 (Pubitemid 36554596)
41. Blandes RA, Keating PJ, McWilliams LJ, George NJR, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46: 681-687
42. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33: 233-239 (Pubitemid 27524701)
43. Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P (2003) Concordant downregulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2
44. Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281: 18763-18773 (Pubitemid 44035537)
45. Momburg F, Koch S (1989) Selective loss of beta 2-microglobulin mRNA in human colon carcinoma. J Exp Med 169: 309-314 (Pubitemid 19035561)
46. Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ (2007) Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol 105: 593-599 (Pubitemid 46734204)
47. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Downregulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154: 745-754 (Pubitemid 29122593)
48. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65: 7926-7933 (Pubitemid 41297271)
49. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leucocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clinical Cancer Res 11: 2552-2560 (Pubitemid 40569453)
50. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206 (Pubitemid 350159921)
51. Wright KL, White LC, Kelly A, Beck S, Trowsdale J, Ting JP (1995) Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med 181: 1459-1471
52. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR (2007) Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141: 41-50 (Pubitemid 44918077)
53. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61 (Pubitemid 46067386)
54. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15: 1499-1509
55. Clarke C, Smyth MJ (2007) Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 25: 192-193 (Pubitemid 46227117)